89Bio Inc reports results for the quarter ended December 31 - Earnings Summary

• 89Bio Inc ETNB.OQ reported a quarterly adjusted loss of $1.02​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -50 cents. The mean expectation of seven analysts for the quarter was for a loss of 77 cents per share. Wall Street expected results to range from $-1.03 to -53 cents per share.

• Reported revenue was zero​; analysts expected zero.

• 89Bio Inc's reported EPS for the quarter was a loss of $1.02​.

• The company reported a quarterly loss of $118.35 million.

• 89Bio Inc shares had risen by 17.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for 89Bio Inc is $33.00

This summary was machine generated from LSEG data February 27 at 11:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)